|
🐜
|
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
12 auth.
L. Novakova,
H. Zetterberg,
P. Sundström,
M. Axelsson,
M. Khademi,
M. Gunnarsson,
...
C. Malmeström,
A. Svenningsson,
T. Olsson,
F. Piehl,
K. Blennow,
J. Lycke
|
8 |
2017 |
8
🐜
|
|
🐜
|
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
99 auth.
J. Kuhle,
G. Disanto,
R. Dobson,
R. Adiutori,
L. Bianchi,
J. Topping,
J. Bestwick,
U. Meier,
M. Marta,
G. Costa,
T. Runia,
E. Evdoshenko,
N. Lazareva,
E. Thouvenot,
P. Iaffaldano,
...
V. Direnzo,
M. Khademi,
F. Piehl,
M. Comabella,
M. Sombekke,
J. Killestein,
H. Hegen,
S. Rauch,
S. D'alfonso,
J. Álvarez-cermeño,
P. Kleinova,
D. Horáková,
Romy Roesler,
F. Lauda,
S. Llufriu,
Timuçin Avşar,
U. Uygunoğlu,
A. Altıntaş,
S. Saip,
T. Menge,
C. Rajda,
R. Bergamaschi,
N. Moll,
M. Khalil,
R. Marignier,
I. Dujmovic,
Henrik Larsson,
C. Malmeström,
E. Scarpini,
C. Fenoglio,
S. Wergeland,
A. Laroni,
Viviana Annibali,
S. Romano,
A. Martínez,
A. Carrá,
M. Salvetti,
A. Uccelli,
Ø. Torkildsen,
K. Myhr,
D. Galimberti,
K. Rejdak,
J. Lycke,
J. Frederiksen,
J. Drulovic,
C. Confavreux,
D. Brassat,
C. Enzinger,
S. Fuchs,
I. Boscá,
J. Pelletier,
C. Picard,
E. Colombo,
D. Franciotta,
T. Derfuss,
R. Lindberg,
Ö. Yaldizli,
L. Vécsei,
B. Kieseier,
H. Hartung,
P. Villoslada,
A. Siva,
A. Saiz,
H. Tumani,
E. Havrdová,
L. Villar,
M. Leone,
N. Barizzone,
F. Deisenhammer,
C. Teunissen,
X. Montalban,
M. Tintoré,
T. Olsson,
M. Trojano,
S. Lehmann,
G. Castelnovo,
Lapin Sv,
R. Hintzen,
L. Kappos,
R. Furlan,
V. Martinelli,
G. Comi,
S. Ramagopalan,
G. Giovannoni
|
8 |
2015 |
8
🐜
|
|
🐜
|
Rituximab in multiple sclerosis
14 auth.
J. Salzer,
Rasmus Svenningsson,
Peter Alping,
L. Novakova,
Anna Björck,
K. Fink,
Protik Islam-Jakobsson,
C. Malmeström,
M. Axelsson,
Mattias Vågberg,
...
P. Sundström,
J. Lycke,
F. Piehl,
A. Svenningsson
|
8 |
2016 |
8
🐜
|
|
🐜
|
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
12 auth.
Peter Alping,
T. Frisell,
L. Novakova,
Protik Islam-Jakobsson,
J. Salzer,
Anna Björck,
...
M. Axelsson,
C. Malmeström,
K. Fink,
J. Lycke,
A. Svenningsson,
F. Piehl
|
7 |
2016 |
7
🐜
|
|
🐜
|
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
12 auth.
M. Gunnarsson,
C. Malmeström,
M. Axelsson,
P. Sundström,
C. Dahle,
M. Vrethem,
...
T. Olsson,
F. Piehl,
N. Norgren,
L. Rosengren,
A. Svenningsson,
J. Lycke
|
7 |
2011 |
7
🐜
|
|
🐬
|
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
M. Axelsson,
C. Malmeström,
Staffan Nilsson,
Sara Haghighi,
Lars Rosengren,
J. Lycke
|
7 |
2010 |
7
🐬
|
|
🐜
|
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
9 auth.
L. Novakova,
M. Axelsson,
M. Khademi,
H. Zetterberg,
K. Blennow,
C. Malmeström,
...
F. Piehl,
T. Olsson,
J. Lycke
|
7 |
2017 |
7
🐜
|
|
🐜
|
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
12 auth.
Jesse Huang,
M. Khademi,
L. Fugger,
Ö. Lindhe,
L. Novakova,
M. Axelsson,
...
C. Malmeström,
C. Constantinescu,
J. Lycke,
F. Piehl,
T. Olsson,
I. Kockum
|
6 |
2020 |
6
🐜
|
|
🐜
|
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
11 auth.
P. Sørensen,
J. Lycke,
J. Erälinna,
A. Edland,
Xingchen Wu,
J. Frederiksen,
...
A. Oturai,
C. Malmeström,
E. Stenager,
F. Sellebjerg,
H. Søndergaard
|
6 |
2011 |
6
🐜
|
|
🐜
|
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
7 auth.
M. Axelsson,
C. Malmeström,
M. Gunnarsson,
H. Zetterberg,
P. Sundström,
J. Lycke,
...
A. Svenningsson
|
6 |
2014 |
6
🐜
|
|
🐬
|
Acyclovir Levels in Serum and Cerebrospinal Fluid after Oral Administration of Valacyclovir
J. Lycke,
C. Malmeström,
L. Ståhle
|
6 |
2003 |
6
🐬
|
